Vioxx: Too Risky for Merck?

Kellogg School of Management Cases

ISSN: 2474-6568

Publication date: 20 January 2017


This case allows the students to examine the various steps of Vioxx's development and launch. By doing so, they can consider whether the decision-making process broke down and why. By connecting the Vioxx launch and withdrawal to changes in Merck's cash flow and stock market value, the students can document the impact of such decisions on the value of the firm.



Petersen, M. and Singhal, R. (2017), "Vioxx: Too Risky for Merck?", Kellogg School of Management Cases.

Download as .RIS



Kellogg School of Management

Copyright © 2007, The Kellogg School of Management at Northwestern University

Please note you might not have access to this content

You may be able to access this content by login via Shibboleth, Open Athens or with your Emerald account.
If you would like to contact us about accessing this content, click the button and fill out the form.